{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:22:43Z","timestamp":1768483363275,"version":"3.49.0"},"reference-count":67,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s269324","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T21:47:08Z","timestamp":1614635228000},"page":"183-192","source":"Crossref","is-referenced-by-count":2,"title":["Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma"],"prefix":"10.2147","volume":"Volume 17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-7072","authenticated-orcid":true,"given":"Barbara","family":"Jezer\u0161ek Novakovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u010dka","family":"Bolte\u017ear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Novakovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21037\/aol.2019.09.01","volume":"3","author":"Sarkozy","year":"2019","journal-title":"Ann Lymphoma"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2478\/v10019-012-0002-6","volume":"46","author":"Gregoric","year":"2012","journal-title":"Radiol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.3892\/ol.2018.7774","volume":"15","author":"Horvat","year":"2018","journal-title":"Oncol Lett"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"V116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1200\/JCO.2018.36.15_suppl.7545","volume":"36","author":"Nabhan","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s40265-016-0650-8","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"ref10","unstructured":"European Medicines Agency. Pixuvri (pixantrone dimaleate): summary of product characteristics [document on the Internet]; 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pixuvri-epar-product-information_en.pdf. Accessed October 10, 2020."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","volume":"13","author":"Pettengell","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2217\/fon-2016-0137","volume":"12","author":"Belada","year":"2016","journal-title":"Future Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1182\/blood-2018-99-112455","volume":"132","author":"Salles","year":"2018","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.16255","volume":"188","author":"Pettengell","year":"2020","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14021","volume":"173","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/ejh.13392","volume":"104","author":"Sancho","year":"2020","journal-title":"Eur J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3892\/ol.2020.11288","volume":"19","author":"Novakovic","year":"2020","journal-title":"Oncol Lett"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1200\/JCO.2019.37.15_suppl.7521","volume":"37","author":"Maddocks","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref25","unstructured":"Karyopharm Therapeutics Inc.. Karyopharm announces FDA approval of XPOVIO\u00ae (selinexor) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [press release on the Internet]; 2020. Available from: https:\/\/investors.karyopharm.com\/2020-06-22-Karyopharm-Announces-FDA-Approval-of-XPOVIO-R-selinexor-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL. Accessed January 22, 2021."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2147\/OTT.S34055","volume":"7","author":"Volpetti","year":"2014","journal-title":"Onco Targets Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","volume":"368","author":"Sawyer","year":"2013","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.228650","volume":"356","author":"Hasinoff","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1021\/acs.chemrestox.6b00190","volume":"29","author":"Menna","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1124\/jpet.112.200568","volume":"344","author":"Salvatorelli","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1517\/21678707.2015.1042454","volume":"3","author":"Pettengell","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1093\/nar\/gkm285","volume":"35","author":"Evison","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/15384047.2015.1070979","volume":"16","author":"Beeharry","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/030089160108700611","volume":"87","author":"Beggiolin","year":"2001","journal-title":"Tumori"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10637-007-9037-8","volume":"25","author":"Cavalletti","year":"2007","journal-title":"Invest New Drugs"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.reprotox.2014.02.006","volume":"46","author":"Longo","year":"2014","journal-title":"Reprod Toxicol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1023\/a:1011139016294","volume":"12","author":"Borchmann","year":"2001","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"ref38","first-page":"43","volume":"7","author":"Faivre","year":"2001","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/s0959-8049(00)00342-7","volume":"36","author":"Dawson","year":"2000","journal-title":"Eur J Cancer"},{"key":"ref40","first-page":"888","volume":"88","author":"Borchmann","year":"2003","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.14101","volume":"174","author":"Pettengell","year":"2016","journal-title":"Br J Haematol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40261-018-0635-3","volume":"38","author":"Pettengell","year":"2018","journal-title":"Clin Drug Investig"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/annonc\/mdt289","volume":"24","author":"Herbrecht","year":"2013","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"ref44","unstructured":"University of Freiburg. R-CPOP as first-line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL. Available from: https:\/\/www.clinicaltrialsregister.eu\/. EudraCT number: 2014\u2013005069-60. Accessed October 10, 2020."},{"key":"ref45","first-page":"813","volume":"2","author":"Marks","year":"2018","journal-title":"HemaSphere"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3109\/10428194.2010.546016","volume":"52","author":"Borchmann","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1182\/blood.V124.21.5435.5435","volume":"124","author":"d\u2019Amore","year":"2014","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1182\/blood.V128.22.1782.1782","volume":"128","author":"Clausen","year":"2016","journal-title":"Blood"},{"key":"ref49","first-page":"5235","volume":"130","author":"Barrenetxea Lekue","year":"2017","journal-title":"Blood"},{"key":"ref50","unstructured":"Aarhus University Hospital. Phase 1\/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD20 positive tumors, rituximab in patients with relapsed aggressive non-hodgkin lymphomas of B- or T-cell phenotype - the P[R]EBEN study. Available from: https:\/\/www.clinicaltrialsregister.eu\/. EudraCT No. 2015-000758-39. Accessed October 10, 2020."},{"key":"ref51","first-page":"808","volume":"2","author":"J\u00f8rgensen","year":"2018","journal-title":"HemaSphere"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/hon.2440_7","volume":"35","author":"d\u2019Amore","year":"2017","journal-title":"Hematol Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.pharep.2019.02.001","volume":"71","author":"D\u0142ugosz-Danecka","year":"2019","journal-title":"Pharmacol Rep"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1080\/10428190601060496","volume":"48","author":"Lim","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"7578","DOI":"10.1200\/jco.2006.24.18_suppl.7578","volume":"24","author":"Santoro","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1002\/cncr.26121","volume":"117","author":"Srokowski","year":"2011","journal-title":"Cancer"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1517\/14740338.2015.1010505","volume":"14","author":"Boyle","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"ref58","unstructured":"European Medicines Agency. Pixuvri (pixantrone): CHMP assessment report [document on the Internet]. London: Committee for Medicinal Products for Human Use (CHMP); 2012. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/pixuvri-epar-public-assessment-report_en.pdf. Accessed October 10, 2020."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1586\/ehm.12.61","volume":"6","author":"Papadatos-Pastos","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00277-019-03749-0","volume":"98","author":"Barrenetxea Lekue","year":"2019","journal-title":"Ann Hematol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/HS9.0000000000000052","volume":"2","author":"Borchmann","year":"2018","journal-title":"HemaSphere"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjh.16259","volume":"188","author":"Eyre","year":"2020","journal-title":"Br J Haematol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hon.2425","volume":"36","author":"Luminari","year":"2018","journal-title":"Hematol Oncol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet Haematol"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=67253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=67253","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T21:47:29Z","timestamp":1614635249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/current-opinion-on-pixantrone-in-the-treatment-of-non-hodgkin-b-cell-l-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":67,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s269324","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}